A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Belzutifan (Primary)
- Indications Gastrointestinal stromal tumours; Neuroendocrine tumours; Pancreatic cancer; Paraganglioma; Phaeochromocytoma; Solid tumours; Von Hippel-Lindau disease
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 16 Jul 2023 Planned number of patients changed from 322 to 337.
- 16 Jul 2023 Planned number of patients changed from 322 to 337.
- 20 Mar 2023 Planned number of patients changed from 232 to 322.